Diabetes Drug Altered Gut Health in Animal Study

Researchers found a common medication modified colon metabolism and gene expression in mice fed a Western diet.

Updated on Sept. 23, 2026 in Nutrition

Isometric editorial illustration of stylized, repeating cellular biological structures in teal and cream, representing metabolic processes in the colon.
A 10-week laboratory study found that the diabetes medication empagliflozin altered fatty acid metabolism and reduced fibrosis-related gene expression in the colons of mice. AI Illustration. Upload story photo >

Live Poll

Does new research on diet and metabolic health influence your personal dietary choices?

In a 10-week study of mice fed a Western diet, administration of the drug empagliflozin was linked to changes in colonic fatty acid metabolism and reduced expression of fibrosis-related genes. This laboratory-based analysis explores how the drug might interact with metabolic changes brought on by diet.

Why it matters

Understanding how diabetes medications influence the gut may reveal new insights into metabolic health and the way specific drugs affect the body beyond their primary use. This preliminary animal data provides a foundation for investigating how future treatments might better address metabolic deterioration.

This preclinical study involved C57BL/6J mice fed a Western or control diet for 10 weeks, identifying 1,136 genes that shifted in response to empagliflozin. The interaction effect between the drug and the diet was statistically significant at p = 0.001.

The details

The drug appears to function by activating fatty acid metabolism within the colon and suppressing genes associated with fibrosis. The mechanism involves modulation of the Peroxisome proliferator-activated receptor alpha and the Nuclear factor kappa B subunit p65. By utilizing transcriptomics and 16S amplicon sequencing, the researchers observed how these pathways are influenced during metabolic stress caused by a high-fat diet.

Timeline

  1. The diet and drug intervention lasted for a period of 10 weeks.

Health Landscape

This study expands upon the current investigation into the SGLT2 inhibitor class of diabetes medications by examining potential extraglycemic effects on the intestinal environment. It contributes to the evolving understanding of how metabolic therapies might influence the gut microbiome.

This study is preliminary animal research and does not change how you should manage your existing health conditions or medications. If you have questions about your metabolic health or your current treatment plan, these are topics best discussed with your physician.

The takeaway

While this laboratory analysis demonstrates a potential interaction between diabetes medication and gut metabolic pathways, these findings are limited to animal models. Readers should remain focused on established clinical guidelines for metabolic health and discuss any health concerns with their doctor.

Further reading

For broader context on how dietary patterns influence metabolic function, visit our Nutrition section.

More information

You can view the original peer-reviewed research article to learn more about the methodology and findings.

Source note: This article includes information reported by Nature.

Live Poll

Does new research on diet and metabolic health influence your personal dietary choices?